For years, I’ve been writing about how uneasy I feel about my doctor’s recommendation that I take statin drugs. As you probably know, I’ve been in the alternative health publishing business since the early 1980s, so I’m very much aware of how unpopular statins are with doctors and scientists who are, like me, suspicious of many of the established protocols favored by mainstream medicine. And the doubts we have are not based on some vague preference for “natural” remedies, but on hundreds and hundreds of published scientific studies that refute or cast doubt on many of the “facts” that mainstream medicine holds to be true.

Statins are promoted to the public as drugs that prevent heart disease and extend life. Most patients come away believing that if they take a statin, lower their cholesterol, and follow instructions, they will live longer.

That promise dissolves when you look carefully at the data. Statins reliably improve bloodwork numbers, especially LDL cholesterol. They do what they are designed to do in that narrow sense. What they do not reliably do for people using them for primary prevention is extend life in any meaningful way. In many large trials, the average life extension amounts to days, sometimes a few weeks, and rarely more.

Did you get that? Those are the facts. (I checked with Nigel, and he is predisposed to mainstream medicine!) Isn’t it insane?

So, you must be thinking, “If that’s so, then why did my doctor write me a prescription for statins? And why do thousands of doctors write prescriptions for millions of Americans to do the same?”

The answer is logical and depressingly obvious once you hear it. Doctors recommend statins because they would be foolish to do otherwise. They operate within professional protocols that opine on “best practices” for treating health issues. Those protocols come from the American Heart Association, the AMA, the CDC, and similar bodies. And once a protocol becomes the standard of care, deviating from it carries legal and professional risk. So even when a doctor knows that they don’t prolong life and do cause adverse side effects, so long as those side effects are not crippling or life-threatening, it would be stupid for them NOT to recommend them.

And why do those major public agencies recommend statins? There are several reasons that all have the same root cause: They rely heavily on population-level statistics and relative risk reductions. A 25% relative reduction sounds impressive. A 2% absolute reduction does not. A recent study comparing American and Japanese patients made this gap visible. When people were shown what statins deliver in absolute terms, most concluded the benefit was not worth the commitment.

But patients are routinely NOT given that information. If they were told that the statins would – at best – extend their life by a week or two while causing all sorts of undesirable side effects, most of them would say, “No, thanks, Doc. I think I’m okay going with alternative solutions, like losing weight and stopping my smoking, etc.”

But the size of the worldwide statin market is between $14 billion and $17 billion annually. And if 80% of all those given this information decided not to take statins, Big Pharma would suffer bigly.

In Short…

Statins do what they are designed to do – lower LDL cholesterol. But that does not reliably translate into meaningful life extension for healthy people. When you look at absolute benefit numbers, the effects are small. In many cases, hundreds of people have to be treated for years to prevent a single event or death. Meanwhile, reports of muscle complaints, metabolic changes, and other side effects are not trivial. For people without existing cardiovascular disease, the decision to take a statin deserves honest, absolute-risk conversation, not marketing spin.

Just the Facts 

Statins Lower Cholesterol but Do Very Little to Prolong Life in Healthy People
* In large-pooled trial data for primary prevention (people without known heart disease), statins showed only very small or non-statistically significant reductions in mortality. Absolute mortality benefits are tiny (about 0.1–0.4% absolute difference). Meaning hundreds of people must be treated for years to prevent one death.

* In low-risk individuals (e.g., <10–20% 10-year cardiovascular risk), statins do not significantly reduce all-cause mortality. Some meta-analyses found relative risk close to neutral (RR ≈ 0.99) for serious illness overall.

* All-cause mortality in low-risk groups generally shows no statistically significant reduction or a reduction on the order of <0.5% over years of treatment.

* A recent evaluation found that statins might prevent one major adverse cardiovascular event per 100 people treated for 2.5 years, but no clear mortality benefit in adults without existing disease.

The Takeaway: The drugs reliably lower LDL (“bad” cholesterol), but that does not translate into longer life for people without existing cardiovascular disease.

(Source: Systematic reviews of primary prevention trials)

Cholesterol Counts Are Poor Predictors of Longevity in Healthy Populations
* LDL cholesterol reduction is the primary biochemical effect of statins, and guidelines focus on lowering LDL levels. However, clinical outcomes do not always mirror surrogate marker improvements.

* Lowering LDL does not necessarily produce meaningful longevity benefits in people without pre-existing disease. In large primary prevention groups, lowering LDL often changes numbers without clinically significant increases in lifespan.

* Some older cholesterol-raising drugs (e.g., niacin) improve HDL but do not reduce all-cause mortality or heart attacks, underscoring the fact that modifying surrogate lipid markers doesn’t always change real outcomes.

The Takeaway: Cholesterol metrics are useful in research but are not reliable standalone predictors of longevity, especially among healthy middle-aged people.

(Source: Large clinical trial biomarker data)

Statins Can Cause Significant Side Effects
* Muscle symptoms: Statins are associated with a range of muscle-related complaints (myalgia, cramps, weakness). And while large trials sometimes underreport them, real-world analyses and observational data show these effects occur meaningfully among patients.

* Myopathy and rare serious muscle damage (rhabdomyolysis): These are uncommon but recognized potential effects, increasing with higher doses.

* Diabetes risk: Statin therapy has been associated with an elevated risk of new-onset diabetes mellitus in some analyses.

Moreover: Adverse event rates vary, and large meta-analyses sometimes find little difference between statins and placebo for specific symptoms. But the reality of side effects remains clinically relevant, particularly in patients who do not clearly benefit.

(Source: Pharmacovigilance data and observational cohorts)

Putting the Numbers into Context
If you treated 100 people without cardiovascular disease with a statin for 5–7 years:
*~1 person might avoid a major cardiovascular event.
* Most will experience no clear improvement in lifespan.
* A non-trivial percentage (5–20%) might report muscle complaints.
* A small subset may develop impaired glucose metabolism.
* A very small number could face serious adverse effects.

Summary
* Statins reliably lower LDL cholesterol, but cholesterol levels are an imperfect surrogate for lifespan. Improvements in lipid numbers do not necessarily translate into meaningful longevity benefits in healthy populations.

* Randomized evidence shows minimal mortality advantage in primary prevention, especially for low-risk individuals.

* Statin side effects – especially muscle symptoms and metabolic changes – are real and can be significant for many patients, even if some large trials underreport them.

By a happy coincidence, I received this video link last week from regular contributor Joe Seta about Peter Atia, a doctor/ internet guru who initially impressed me with his vlogs and blog posts. Watch it to get a very credible explanation of how Atia was wrong about statin drugs and a suggestion as to why.